What is the evidence for switching to enzalutamide after abiraterone failure in metastatic castration‑resistant prostate cancer?

Switching to Enzalutamide After Abiraterone Failure in mCRPC: Not Recommended

After abiraterone failure in metastatic castration-resistant prostate cancer, switching to enzalutamide is not the optimal strategy—docetaxel chemotherapy should be the preferred next-line treatment instead. 1

Guideline-Based Recommendation

The 2025 ASCO guidelines explicitly state that for patients who received prior ARPI (androgen receptor pathway inhibitor), the panel recommends docetaxel chemotherapy 1. This recommendation is based on the recognition that cross-resistance between abiraterone and enzalutamide significantly limits the efficacy of sequential ARPI therapy.

Why Not Switch Between ARPIs?

The NCCN guidelines (2023) reinforce this position, noting that "data suggest that giving the alternate novel hormone therapy may not be the optimal strategy considering the availability of other treatment options, including chemotherapy" and that "data suggest cross-resistance between abiraterone and enzalutamide" 2.

Real-World Evidence of Limited Benefit

When enzalutamide is used after abiraterone failure, the results are disappointing:

• PSA response rates drop dramatically: Only 27% of patients achieved any PSA response after switching from abiraterone to enzalutamide 3
• Median progression-free survival is short: Just 8.1 months in the post-abiraterone setting 3
• Cross-resistance is common but not universal: Among patients who failed abiraterone, only 43.8% of those initially abiraterone-sensitive and 15.8% of abiraterone-resistant patients showed >50% PSA decline with enzalutamide 4
• Duration of benefit is limited: Median time on enzalutamide after abiraterone was only 4.7 months compared to 9.1 months in ARPI-naive patients 5

Sequence Matters

One study suggests that abiraterone followed by enzalutamide may be slightly more efficacious than the reverse sequence 6, with significantly better second-line PSA response rates (30% vs 6.4%, p=0.004). However, this modest benefit does not overcome the fundamental issue of cross-resistance.

Preferred Treatment Algorithm After Abiraterone Failure

Step 1: Obtain molecular testing

• Test for BRCA1/2 and other HRR gene alterations
• Consider PSMA PET imaging if available

Step 2: Choose next therapy based on molecular profile:

If BRCA1/2 positive:

• PARP inhibitor monotherapy (olaparib) is the preferred option 1
• This showed OS benefit (HR 0.63) in the PROfound trial 1

If PSMA-positive and post-docetaxel:

• 177Lu-PSMA-617 is recommended 1
• Superior to cabazitaxel with better PSA response (66% vs 37%) and fewer grade 3-4 adverse events 2

If no actionable biomarkers:

• Docetaxel chemotherapy is the standard recommendation 1
• If already received docetaxel, consider cabazitaxel or 177Lu-PSMA-617 1

Special situations:

• Symptomatic bone-only disease: Radium-223 1
• MSI-H/dMMR tumors: Pembrolizumab 1
• Indolent disease: Sipuleucel-T may be considered 1

Critical Pitfall to Avoid

Do not reflexively switch between ARPIs without considering chemotherapy or biomarker-directed therapy. The CARD trial demonstrated that cabazitaxel significantly outperformed switching to the alternate ARPI (enzalutamide or abiraterone) in patients who had received docetaxel and one prior ARPI, with improved PFS (HR 0.54) and OS (HR 0.64) 1, 2.

When Enzalutamide Might Still Be Considered

While not optimal, enzalutamide after abiraterone may be considered in highly selected circumstances:

• Patients who are chemotherapy-ineligible due to poor performance status or comorbidities
• Those who had a prolonged, robust response to abiraterone (suggesting less cross-resistance)
• Patients declining chemotherapy after informed discussion
• As a bridge therapy while awaiting molecular testing results

Even in these scenarios, approximately 27-46% of patients may achieve some PSA decline 3, 7, though durability is limited.

Bottom Line

The evidence clearly demonstrates that sequential ARPI therapy (abiraterone → enzalutamide) results in diminished efficacy due to cross-resistance mechanisms. Current guidelines prioritize docetaxel chemotherapy, PARP inhibitors for HRR-altered tumors, or radiopharmaceuticals for appropriate candidates over switching between ARPIs 1.